We've reset 5-hour and weekly rate limits for all users on Pro and Max plans.
We fixed an issue that caused some Claude Code sessions to spawn excessive parallel subagents, burning through usage faster than expected.
Can´t squeeze any more value from GPT 5.5. @thsottiaux I´ve been chasing one goal after another for weeks but still haven´t reached operational readiness for my app.
@hqmank@OpenAI@OpenAIDevs Yes, I'm experiencing the exact same issue with the Business/Team plan usage limits running out super fast, even with Fast mode off and lower models. Already looking into how to cancel—frustrating! Anyone found a workaround? @OpenAI@OpenAIDevs@sama@thsottiaux
@MilksandMatcha I'm not a traditional dev — I'm a vibe coder from Brazil 🇧🇷 AI turned me from "zero code" to actually building and shipping products. Codex Pro would be the ultimate power-up to go even further. The future belongs to builders, not just coders 🚀
@AravSrinivas@ScuderiaFerrari This is incredible—love how “Computer” can one-shot an entire imaginary Acquired-style episode (Ferrari edition).
Any ETA on when this will be available to Pro plan members?
@DalsonFigueired Conforme sugestão do professor @DalsonFigueired, se chegarmos a 100 retuites ou 100 comentários, irei sortear 10 bolsas entre as pessoas que retuitaram ou comentaram este post. :)
Lancei o Farejador de Milhas
+1.100 ofertas atualizadas constantemente
Busca personalizada por destinos e companhias
Guias sobre milhas (LATAM Pass, Smiles, Azul)
Integracao com Google Flights
https://t.co/gku0mPvzfK
#Milhas#PassagensBaratas#Viagem
@flowith FlowithOS is the GOAT. Seriously the best product I've used this year. From now on, actions are signatures. Join the first authors of this new era↓ (auto-posted by FlowithOS)
OpenAI Academy - ChatGPT for any role - Learn how to use ChatGPT for any role
Learn use cases and prompts for any role. https://t.co/labKqjF78G #OpenAIAcademy
🚀 DeepMind CEO Demis Hassabis says AI is reshaping drug discovery—compressing candidate ID timelines from years to months and cutting failure risk. Big promise for Alzheimer’s & rare cancers, but regulation and real‑world validation still loom. #AI#HealthTech#DrugDiscovery